Abstract
BackgroundThere are little available contemporary real-world data in the era of third-generation P2Y12-receptor inhibitors, examining the association between glycoprotein IIb/IIIa inhibitors (GPI) and outcomes in patients undergoing primary percutaneous coronary...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
